{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:04:17Z","timestamp":1787065457697,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd005425","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T00:00:00Z","timestamp":1386633600000}}],"reference-count":57,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005425.pub2","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T12:14:08Z","timestamp":1386677648000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Lipid-lowering agents for nephrotic syndrome"],"prefix":"10.1002","volume":"2013","author":[{"given":"Xiangyu","family":"Kong","sequence":"first","affiliation":[{"name":"Chengdu Medical College; Department of Epidemiology and Biostatistics, School of Public Health; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Evidence-Based Medicine and Clinical Epidemiology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"Fan","sequence":"additional","affiliation":[{"name":"Luzhou Medical College; Department of Nephrology; No. 319 Zhong Shan Road Luzhou Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Li","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Nephrology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taixiang","family":"Wu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanhui","family":"Jiang","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Chinese Evidence-Based Medicine Centre; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,10]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0001|cit1","first-page":"40","article-title":"The effects of\u00a0gemfibrozil\u00a0on hyperlipidaemia in children with persistent\u00a0nephrotic syndrome","volume":"44","author":"Buyukcelik","year":"2002","journal-title":"Turkish Journal of Pediatrics"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0002|cit2","unstructured":"Gheith O Saad M Sobh M Nephrotic dyslipidaemia, harvest of treatment [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 258"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005425.pub2-BIB0003|cit3","first-page":"100","article-title":"Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]","volume":"17","author":"Gheith","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005425.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000065021","article-title":"Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome","volume":"91","author":"Gheith","year":"2002","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"e57\u2013e61","DOI":"10.1016\/j.ejim.2008.08.012","article-title":"Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report","volume":"20","author":"Gheith","year":"2009","journal-title":"European Journal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10157-008-0033-x","article-title":"Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia","volume":"12","author":"Gheith","year":"2008","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl 71","key":"10.1002\/14651858.CD005425.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1523-1755.1999.07128.x","article-title":"Simvastatin in nephrotic syndrome","volume":"56","author":"Olbricht","year":"1999","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD005425.pub2-BIB0008|cit8","first-page":"143","article-title":"Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome","volume":"5","author":"Sharma","year":"2004","journal-title":"Indian Academy of Clinical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0022-2275(20)39766-2","article-title":"Physiologic mechanisms of action of lovastatin in nephrotic syndrome","volume":"36","author":"Aguilar-Salinas","year":"1995","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0010|cit10","first-page":"14","article-title":"Effect of hilsha fish oil on lipid profile in patients with nephrotic syndrome","volume":"20","author":"Chowdhury","year":"2001","journal-title":"Bangladesh Renal Journal"},{"issue":"11","key":"10.1002\/14651858.CD005425.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1093\/ndt\/gfr072","article-title":"Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy","volume":"26","author":"Cruzado","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2-5","key":"10.1002\/14651858.CD005425.pub2-BIB0012|cit12","first-page":"203","article-title":"Effect of dietary manipulation on the lipid abnormalities and urinary protein loss in nephrotic patients","volume":"18","author":"D'Amico","year":"1992","journal-title":"Mineral & Electrolyte Metabolism"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD005425.pub2-BIB0013|cit13","first-page":"65","article-title":"Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients","volume":"39","author":"D'Amico","year":"1991","journal-title":"Kidney International - Supplement"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0014|cit14","first-page":"237","article-title":"Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome","volume":"35","author":"D'Amico","year":"1991","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0015|cit15","unstructured":"Gentile MG D'Amico G Redaelli L Gotti E Perticucci E de Biase V Dietary treatment of hyperlipidaemia in patients with nephrotic syndrome. [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo (Japan) 1990 121A"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0026-0495(96)90138-9","article-title":"The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment","volume":"45","author":"Dullaart","year":"1996","journal-title":"Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0017|cit17","first-page":"385","article-title":"The serum lathosterol\/cholesterol ratio, an index of cholesterol synthesis, is not elevated in human nephrotic syndrome and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment [abstract]","volume":"6","author":"Dullaart","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00467-009-1128-7","article-title":"Efficacy of simvastatin in children with hyperlipidaemia secondary to kidney disorders","volume":"24","author":"Garc\u00eda-de-la-Puente","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005425.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0272-6386(89)80038-1","article-title":"Lovastatin in the treatment of multifactorial hyperlipidaemia associated with proteinuria","volume":"13","author":"Golper","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005425.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ki.1989.189","article-title":"Treatment of nephrotic hyperlipoproteinaemia with gemfibrozil","volume":"36","author":"Groggel","year":"1989","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0021|cit21","unstructured":"Kaliev RR Sydykova AT Mirrakhimov EM Effect of lovastatin, exogenous hypobaric hypoxia and its combination on hyperlipidaemia in patients with nephrotic glomerulo-nephritis [abstract] 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna (Austria) 2001 151"},{"issue":"8624","key":"10.1002\/14651858.CD005425.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(88)90870-7","article-title":"Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome","volume":"2","author":"Rabelink","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD005425.pub2-BIB0023|cit23","first-page":"219","article-title":"A prospective\u00a0clinical\u00a0trial\u00a0comparing the treatment of idiopathic membranous nephropathy\u00a0and\u00a0nephrotic\u00a0syndrome\u00a0with\u00a0simvastatin\u00a0and diet, versus diet alone","volume":"46","author":"Rayner","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005425.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.thromres.2010.12.020","article-title":"Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism","volume":"127","author":"Resh","year":"2011","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0272-6386(12)70180-4","article-title":"Treatment of hyperlipidaemia in the\u00a0nephrotic\u00a0syndrome: the effects of pravastatin\u00a0therapy","volume":"22","author":"Spitalewitz","year":"1993","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005425.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000013549","article-title":"Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolaemia and combined hyperlipidaemia secondary to the nephrotic syndrome","volume":"20","author":"Toto","year":"2000","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0028|cit28","first-page":"321","article-title":"Pravastatin\u00a0improves hypercholesterolemia of the\u00a0nephrotic\u00a0syndrome\u00a0by enhancing clearance of apolipoprotein B [abstract]","volume":"3","author":"Toto","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0029|cit29","unstructured":"Querfeld U Prospective, multicenter, double-blind, randomised, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidaemia in children with persisting proteinuria controlled-trials.com\/ISRCTN06912061"},{"issue":"8934","key":"10.1002\/14651858.CD005425.pub2-BIB0030|cit30","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Anonymous","year":"1994","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD005425.pub2-BIB0031|cit31","first-page":"1544","article-title":"The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity","volume":"312","author":"Appel","year":"1985","journal-title":"New\u00a0England\u00a0Journal\u00a0of\u00a0Medicine"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0032|cit32","first-page":"110","article-title":"Lipid-lowering\u00a0agents\u00a0in\u00a0proteinuric\u00a0diseases","volume":"10 Suppl 1","author":"Appel\u00a0GB","year":"1990","journal-title":"American\u00a0Journal\u00a0of\u00a0Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD005425.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"269","author":"Anonymous","year":"1993","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/BF00868751","article-title":"Inefficacy of pefloxacin in steroid-responsive nephrotic syndrome","volume":"9","author":"Bagga","year":"1995","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0035|cit35","first-page":"31","article-title":"Hyperlipidaemia\u00a0in\u00a0chronic\u00a0kidney\u00a0disease","volume":"34","author":"Chan","year":"2005","journal-title":"Annals\u00a0of\u00a0the\u00a0Academy\u00a0of\u00a0Medicine, Singapore"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacology\u00a0& Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0037|cit37","first-page":"2214","article-title":"Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency","volume":"56","author":"Culleton","year":"1999","journal-title":"Kidney\u00a0International"},{"issue":"4","key":"10.1002\/14651858.CD005425.pub2-BIB0038|cit38","first-page":"S1","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)","volume":"10","author":"De\u00a0Backer","year":"2003","journal-title":"European\u00a0Journal of\u00a0Cardiovascular\u00a0Prevention &\u00a0Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD005425.pub2-BIB0039|cit39","first-page":"1769","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"European\u00a0Heart\u00a0Journal"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0040|cit40","unstructured":"Zetia (ezetimibe) product information, 2002. Merck\/Schering-Plough Pharmaceuticals Available from http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zetia\/zetia_pi.pdf"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0041|cit41","first-page":"1266","article-title":"Primary glomerular disease - nephrotic syndrome","volume-title":"Brenner & Rector's the Kidney","author":"Falk","year":"2001"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0042|cit42","article-title":"Cholesterol lowering and total mortality","volume-title":"Lowering cholesterol in high-risk individuals and populations","volume":"24","author":"Gordon","year":"1995"},{"issue":"4","key":"10.1002\/14651858.CD005425.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1056\/NEJM196907242810402","article-title":"Progression of \"lipoid nephrosis\" to renal insufficiency","volume":"281","author":"Hayslett","year":"1969","journal-title":"New England Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD005425.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0045|cit45","unstructured":"Higgins J Altman D Sterne J (editors) Chapter 8:\u00a0Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD005425.pub2-BIB0046|cit46","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group","year":"2003","journal-title":"American\u00a0Journal\u00a0of\u00a0Kidney\u00a0Diseases"},{"issue":"8A","key":"10.1002\/14651858.CD005425.pub2-BIB0047|cit47","first-page":"20B","article-title":"Mechanism\u00a0of\u00a0action\u00a0of\u00a0niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"American\u00a0Journal\u00a0of\u00a0Cardiology"},{"issue":"5\u00a0Suppl\u00a03","key":"10.1002\/14651858.CD005425.pub2-BIB0048|cit48","first-page":"S142","article-title":"Hyperlipidemia\u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0renal\u00a0disease","volume":"32","author":"Kasiske","year":"1998","journal-title":"American\u00a0Journal\u00a0of\u00a0Kidney\u00a0Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ki.1994.349","article-title":"Lipids and the kidney","volume":"46","author":"Keane","year":"1994","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD005425.pub2-BIB0050|cit50","first-page":"893","article-title":"Nephrology - nephrotic syndrome","volume-title":"Textbook of medicine","volume":"2","author":"Krishna Das","year":"2002"},{"issue":"6925","key":"10.1002\/14651858.CD005425.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","article-title":"By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordonez","year":"1993","journal-title":"Kidney International"},{"issue":"14","key":"10.1002\/14651858.CD005425.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD005425.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005425.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0272-6386(86)80164-0","article-title":"Treatment of hyperlipidaemia of the nephrotic syndrome: A controlled trial","volume":"8","author":"Valeri","year":"1986","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0272-6386(12)80994-2","article-title":"Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment","volume":"23","author":"Wheeler","year":"1994","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005425.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005425","article-title":"Lipid-lowering agents for nephrotic syndrome","author":"Fan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005425.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T04:32:15Z","timestamp":1735533135000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005425.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,10]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005425.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,10]]}}}